Administered by subcutaneous injection

DUPIXENT® is intended for use under the guidance of a healthcare provider. A patient may self-inject DUPIXENT® or the patient’s caregiver may administer DUPIXENT®. 

In adolescents 12 years of age and older, it is recommended that DUPIXENT® be given by or under the supervision of an adult. The DUPIXENT® pre-filled pen is only for use in adults and adolescents aged 12 years and older. 

The DUPIXENT® pre-filled syringe should be given by a caregiver in children 6-11 years of age. Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT® prior to use, according to the Instructions for Use.1

Showing DUPIXENT dosing in adolescents aged 12 to 17 years, which is based on body weight. In adolescents weighing 60 kilograms or more, the recommended dose of DUPIXENT is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg every other week. In adolescents weighing 30 to less than 60 kilograms, the recommended dose of DUPIXENT is an initial dose of 400 mg (two 200 mg injections), followed by 200 mg every other week. In adolescents weighing 15 to less than 30 kilograms, the recommended dose of DUPIXENT is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg every four weeks.


DUPIXENT® can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved for problem areas only, such as the face, neck, intertriginous and genital areas.1

DUPIXENT® is not a steroid treatment or an immunosuppressant. DUPIXENT® is an immunomodulator.1



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300298
Last updated: 06/2023

paab logo